INTRODUCTION
Transforming growth factor beta (TGF-) has been implicated in virtually every progressive renal disease studied to date. [1, 2] Diabetic nephropathy is no exception. [3] [4] [5] [6] Both dia-betes in vivo and a high glucose environment in vitro increase levels of mRNA for TGF-I in the kidney. [-1 Blockade of TGF-effects prevents diabetic renal hypertrophy in experimental models of diabetes. [7, 8] Most studies have assessed only TGF-31, the most abundant renal isoform of this growth factor. The mammalian kidney also produces isoforms 2 and 3. One study has examined these isoforms in human biopsy specimens from a variety of kidney diseases. [9] All diseases associated with increased extracellular matrix, such as diabetes, showed increased immunostaining for all 3 isoforms in the glomeruli and in the tubulointerstitium. In situ hybridization was also increased for all isoforms, although diabetic specimens were not studied with this technique. Hill et al., recently found that TGF-31, TGF-2, and the type II TGF-receptor (TGFq3RII) all varied over 6 months in 2 experimental models of diabetes. [1] While equivalent in vitro, these isoforms have distinct functions in vivo, as demonstrated by the different phenotypes produced by knock-out mice for each isoform and different effects in wound healing. [5] The present study shows that mRNA and protein for all 3 isoforms increase early in the course of streptozocin diabetes in the rat.
RESEARCH DESIGN AND METHODS

Animals
Twenty male Sprague-Dawley rats, approximately 150 gm body weight and 6 to 8 weeks old, were divided into 2 groups. One (Fig. 1) . Given the different roles of these isoforms in renal development, each may be playing a very specific role in diabetic renal hypertrophy. [11] [12] [13] [14] Most studies of TGF-[3 suppression to date have used nonspecific measures that may suppress the production or function of all isoforms of this growth factor. [7, 18, 19] These studies FIGURE 3 Representative immunohistochemistry studies for saline controls (SC) and streptozocin diabetes (STZ DM) for all isoforms of TGF- [3. suggest that TGF-[3 contributes to diabetic renal hypertrophy, primarily the result of proximal tubular growth. [7] Han et al., have shown that specific blockade of TGF-[I production in the proximal tubule with anti-sense oligonucleotides does attenuate renal hypertrophy; however, renal weight is not suppressed to levels seen in nondiabetic mice. [8] Our study also found increased message for TGF-f31, as other investigators have previously described; [7, 8, 22] Hill et al., report stable levels at day 14 in their study. [ We cannot rule-out cross-reactivity of the isoforms in our ELISA measurements. While the antibodies used in these assays reportedly show <5% cross-reactivity among human isoforms, cross-reactivity has not been assessed in the rat. While our protein levels appear similar in the graph (Fig. 2) [27] further study wili be necessary to determine whether the "statistically-significant" differences shown in the present study also result in "physiologically-significant" differences in the diabetic rat kidney.
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We also cannot completely exclude the possibility that our findings are the result of STZ nephrotoxicity rather than the diabetic state. By two weeks, STZ has been cleared by the rat. We have attempted to use 5-thio-D-glucose, an inhibitor of STZ, to examine this question in the past; however, injection of the inhibitor alone resulted in levels of TGF-f31 mRNA and protein similar to those seen in rats with diabetes. [28] Injection of inhibitor plus STZ was not additive. Hill et al., studied another model of diabetes, the biobreeding rat, which devel-ops diabetes spontaneously. [10] The pattern of expression of the TGF-isoforms was quite similar throughout their study period to that for STZ DM. Thus, it seems likely that these findings result from diabetes and not direct STZ toxicity.
It has been suggested that TGF-f3 is the most appropriate therapeutic target in diabetic kidney disease. [4] Most studies to date have concentrated on TGF-31. While it is the most abundant renal isoform of this growth factor, smaller but significant increases in mRNA and protein for isoforms 2 and 3 occur as well. Future studies need to address specific roles that these isoforms may play in diabetic kidney disease and the effect of therapies on all forms of TGF-f3.
